Clinical pharmacist-led intervention improves anxiety, depression and inhaler technique in budesonide/glycopyrronium/formoterol-using patients: A single-center prospective randomized cohort study.
Meiying Lin, Zhiyong Wang, Zhibin Chen et al.
✦ AI-curated · Sources linked
In 30 seconds
This single-center prospective randomized cohort study evaluated the impact of a clinical pharmacist-led intervention on anxiety, depression, and inhaler technique in 100 patients using budesonide/glycopyrronium/formoterol (BGF). The intervention significantly reduced anxiety and depression scores, with lower moderate-to-severe anxiety rates at 6 months (68.75% vs. 93.33%, p<0.05) and improved inhaler technique scores at all follow-ups.
Key findings
- Lower Self-Rating Anxiety Scale scores in the experimental group at 3 and 6 months (p<0.05).
- Moderate-to-severe anxiety rate decreased from 93.33% to 68.75% at 6 months (p<0.05).
- Improved inhaler technique scores in the experimental group at all follow-ups (p<0.05).
- Adverse drug reaction incidence was lower in the experimental group (2 vs. 5 cases).
Why it matters
The study highlights the potential of clinical pharmacist interventions in managing chronic respiratory disease, addressing not only medication adherence but also mental health and inhaler technique, which are crucial for optimizing treatment outcomes.